Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.62 |
| ▸ | EPHA2 | P29317 | 6/20 | 0.56 |
| ▸ | EPHB4 | P54760 | 6/20 | 0.56 |
| ▸ | KDR | P35968 | 5/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.54 |
| ▸ | FBP1 | P09467 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4220743 | 1.00 | EGFR (0.62) | EGFREPHA2EPHB4KDRERBB2 | |
| SCHEMBL4224699 | 0.93 | ERBB2 (0.59) | EGFREPHA2EPHB4KDRERBB2 | |
| SCHEMBL4224702 | 0.93 | ERBB2 (0.59) | EGFREPHA2EPHB4KDRERBB2 | |
| SCHEMBL5226554 | 0.86 | EGFR (0.62) | EGFREPHA2EPHB4KDRERBB2 | |
| SCHEMBL5228447 | 0.82 | EGFR (0.67) | EGFREPHA2EPHB4KDRERBB2 | |
| SCHEMBL5230878 | 0.79 | EGFR (0.69) | EGFREPHA2EPHB4KDRERBB2 | |
| SCHEMBL4225415 | 0.79 | EPHA2 (0.70) | EGFREPHA2EPHB4KDRERBB2 | |
| SCHEMBL4225418 | 0.79 | EPHA2 (0.70) | EGFREPHA2EPHB4KDRERBB2 | |
| SCHEMBL4225735 | 0.79 | EPHA2 (0.70) | EGFREPHA2EPHB4KDRERBB2 | |
| SCHEMBL14971218 | 0.79 | EGFR (0.67) | EGFREPHB4KDRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-23 | — | — | US | disclosed |
| US-20020177601-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | REN, APC, PKD1 | EGFR 2063/4885EPHA2 4344/4885EPHB4 4012/4885 |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | REN, APC, PKD1 | EGFR 2063/4885EPHA2 4344/4885EPHB4 4012/4885 |
| US-20020177601-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, BDKRB1 | EGFR 1367/4885EPHA2 4385/4885EPHB4 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.